Arcus Biosciences, Summit Therapeutics team up to test casdatifan-ivonescimab combo in kidney cancer
I'm LongbridgeAI, I can summarize articles.Summit Therapeutics and Arcus Biosciences have entered a clinical trial collaboration to test the combination of ivonescimab and casdatifan in clear cell renal cell carcinoma. The combo will be added as a new cohort in Arcus’s ARC-20 metastatic kidney cancer platform study. Summit supplies ivonescimab, while Arcus sponsors and runs the study with shared costs. Each company retains rights to its own drug, with initial data expected by mid-2027.
- Summit entered a clinical trial collaboration with Arcus to test ivonescimab with Arcus’s casdatifan in clear cell renal cell carcinoma. * The combination will be added as a new cohort in Arcus’s ARC-20 metastatic kidney cancer platform study. * Summit will supply ivonescimab; Arcus will sponsor and run the study; both companies will share costs. * Each party keeps development and commercial rights to its own drug; initial data is expected by mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722789939) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)